Immunotherapy combo aims to wipe out High-Risk rectal cancer before surgery
NCT ID NCT07214142
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation can better shrink or eliminate tumors in people with locally advanced rectal cancer that has a high chance of coming back. About 30 participants will receive the combination treatment before surgery. The main goal is to see how many patients have no cancer cells left in their tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 inhibitor (immunotherapy drug) combined with chemotherapy and radiation
- What this could lead to
- If successful, this combination could increase the chance of eliminating all tumor cells before surgery, potentially reducing recurrence risk for high-risk rectal cancer patients.
- What could go wrong
- This is a small, early-phase (Phase 2) single-arm study with only 30 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the added benefit over standard treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can precision protons spare rectal cancer patients from harsh side effects?
- Could a single drug replace surgery for rectal cancer?
- Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
- Blood test and CT combo may spare rectal cancer patients a second surgery
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Radiation may spare early rectal cancer patients from radical surgery